JGC
SCPH

J. Goldman & Co’s scPharmaceuticals SCPH Stock Holding History

J. Goldman & Co’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-121,500
Closed -$463K – 593
2025
Q2 		$463K Sell
121,500
-464,735
-79% -$1.44M 0.01% 388
2025
Q1 		$1.54M Sell
586,235
-632,892
-52% -$2.06M 0.04% 325
2024
Q4 		$4.32M Sell
1,219,127
-160,866
-12% -$616K 0.11% 203
2024
Q3 		$6.29M Buy
1,379,993
+509,656
+59% +$2.47M 0.18% 141
2024
Q2 		$3.79M Sell
870,337
-248,308
-22% -$1.09M 0.11% 194
2024
Q1 		$5.62M Sell
1,118,645
-285,962
-20% -$1.6M 0.18% 141
2023
Q4 		$8.81M Buy
1,404,607
+1,316,700
+1,498% +$7.54M 0.36% 86
2023
Q3 		$626K Buy
87,907
+31,655
+56% +$249K 0.02% 263
2023
Q2 		$573K Sell
56,252
-11,250
-17% -$117K 0.02% 287
2023
Q1 		$612K Sell
67,502
-109,587
-62% -$803K 0.02% 254
2022
Q4 		$1.27M Buy
177,089
+126,464
+250% +$773K 0.06% 205
2022
Q3 		$330K Buy
+50,625
New +$270K 0.02% 314
2022
Q2 		– Sell
-67,500
Closed -$383K – 452
2022
Q1 		$383K Sell
67,500
-302,591
-82% -$1.49M 0.02% 300
2021
Q4 		$1.86M Sell
370,091
-422,330
-53% -$2.32M 0.1% 210
2021
Q3 		$5.27M Buy
792,421
+71,544
+10% +$428K 0.26% 105
2021
Q2 		$4.41M Buy
720,877
+522,451
+263% +$3.15M 0.17% 153
2021
Q1 		$1.32M Buy
+198,426
New +$1.36M 0.04% 280

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

J. Goldman & Co's SCPH Position: Q3 2025 in Review

J. Goldman & Co sold out of scPharmaceuticals (SCPH) in Q3 2025, closing a stake of 121,500 shares — an estimated $463K sold.

J. Goldman & Co first reported a position in SCPH in Q1 2021 and held it in 17 quarters. The position peaked at $8.81M in Q4 2023. 110 funds tracked by Wall St. Rank hold SCPH as of Q3 2025.

  • J. Goldman & Co reported no remaining scPharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 121,500 scPharmaceuticals shares in Q3 2025, an estimated $463K.
  • J. Goldman & Co first reported a position in scPharmaceuticals in Q1 2021 and held it in 17 quarters.
  • J. Goldman & Co's scPharmaceuticals position peaked at $8.81M in Q4 2023.
  • 110 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.